{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:16:36Z","timestamp":1792815396672,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Next-generation selective estrogen receptor-\u03b1 (ER\u03b1) antagonist\/degraders (SERDs) are being developed for ER-positive breast cancer (ER\n                    <jats:sup>+<\/jats:sup>\n                    BC), with intentions of improving outcomes for patients. In recent clinical trials of metastatic ER\n                    <jats:sup>+<\/jats:sup>\n                    BC, next-generation SERDs demonstrated clinical activity, and elacestrant received an approval for advanced\n                    <jats:italic>ESR1<\/jats:italic>\n                    -mutant disease. However, responses to these drugs were highly heterogeneous: across trials and independent of\n                    <jats:italic>ESR1<\/jats:italic>\n                    status, 30\u201350% of patients progressed by their first follow-up scan while other patients sustained benefit for 2 years or more. Here, we interrogate the basis for heterogeneous responses by comparing biopsies from non-responding patients (NR; progression-free survival &lt;2 months) and responding patients (Resp; PFS\u2009\u2265\u20092 months) who received the next-generation SERD giredestrant. While Resp tumors maintain high dependency on ER\u03b1 signaling, NR tumors exhibit loss of luminal lineage identity and by extension, ER\u03b1 dependence. NR tumors instead up-regulate multiple ER\u03b1-independent proliferative pathways, such as EGFR\/MAPK and Hippo\/TEAD, which may represent targetable dependencies in NR disease. Modeling resistance and lineage plasticity in vitro, we find that giredestrant-resistant ER\n                    <jats:sup>+<\/jats:sup>\n                    BC cell lines exhibit profound shifts in chromatin accessibility, with the transcription factors, FOXA1 and FOXM1, implicated in gene expression of NR-upregulated proliferative pathways.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-71233-1","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T01:30:38Z","timestamp":1775007038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Loss of luminal lineage drives resistance to next-generation ER\u03b1 antagonists in pretreated ER+ HER2\u2212 locally-advanced or metastatic breast cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-4614","authenticated-orcid":false,"given":"Jackson","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareem","family":"Heslop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2552-6183","authenticated-orcid":false,"given":"Vasumathi","family":"Kameswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2410-8767","authenticated-orcid":false,"given":"Bence","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8333-9995","authenticated-orcid":false,"given":"Jennifer M.","family":"Giltnane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Aimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Wei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary R.","family":"Gates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Eng-Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Perez-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0472-1254","authenticated-orcid":false,"given":"Komal L.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8937-0873","authenticated-orcid":false,"given":"Nicholas C.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8065-8838","authenticated-orcid":false,"given":"Elgene","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"71233_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"71233_CR2","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/ng.2822","volume":"45","author":"W Toy","year":"2013","unstructured":"Toy, W. et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45, 1439\u20131445 (2013).","journal-title":"Nat. Genet."},{"key":"71233_CR3","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/ng.2823","volume":"45","author":"DR Robinson","year":"2013","unstructured":"Robinson, D. R. et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45, 1446\u20131451 (2013).","journal-title":"Nat. Genet."},{"key":"71233_CR4","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","volume":"20","author":"R Jeselsohn","year":"2014","unstructured":"Jeselsohn, R. et al. Emergence of constitutively active estrogen receptor-\u03b1 mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin. Cancer Res. 20, 1757\u20131767 (2014).","journal-title":"Clin. Cancer Res."},{"key":"71233_CR5","doi-asserted-by":"publisher","first-page":"ra182","DOI":"10.1126\/scitranslmed.aac7551","volume":"7","author":"G Schiavon","year":"2015","unstructured":"Schiavon, G. et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci. Transl. Med. 7, ra182 (2015).","journal-title":"Sci. Transl. Med."},{"key":"71233_CR6","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.cell.2019.06.026","volume":"178","author":"J Guan","year":"2019","unstructured":"Guan, J. et al. Therapeutic ligands antagonize estrogen receptor function by impairing its mobility. Cell 178, 949\u2013963 e918 (2019).","journal-title":"Cell"},{"key":"71233_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1158\/2159-8290.CD-14-0697","volume":"5","author":"M van Kruchten","year":"2015","unstructured":"van Kruchten, M. et al. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer. Cancer Discov. 5, 72\u201381 (2015).","journal-title":"Cancer Discov."},{"key":"71233_CR8","doi-asserted-by":"publisher","first-page":"9334","DOI":"10.1021\/acsomega.0c06362","volume":"6","author":"M Mottamal","year":"2021","unstructured":"Mottamal, M., Kang, B., Peng, X. & Wang, G. From pure antagonists to pure degraders of the estrogen receptor: evolving strategies for the same target. ACS Omega 6, 9334\u20139343 (2021).","journal-title":"ACS Omega"},{"key":"71233_CR9","doi-asserted-by":"publisher","first-page":"11841","DOI":"10.1021\/acs.jmedchem.1c00847","volume":"64","author":"J Liang","year":"2021","unstructured":"Liang, J. et al. GDC-9545 (Giredestrant): a potent and orally bioavailable selective estrogen receptor antagonist and degrader with an exceptional preclinical profile for ER+ breast cancer. J. Med. Chem. 64, 11841\u201311856 (2021).","journal-title":"J. Med. Chem."},{"key":"71233_CR10","doi-asserted-by":"publisher","first-page":"eabo5959","DOI":"10.1126\/scitranslmed.abo5959","volume":"14","author":"J Liang","year":"2022","unstructured":"Liang, J. et al. Giredestrant counters a progesterone hypersensitivity program driven by estrogen receptor mutations in breast cancer. Sci. Transl. Med. 14, eabo5959 (2022).","journal-title":"Sci. Transl. Med."},{"key":"71233_CR11","doi-asserted-by":"publisher","unstructured":"Bidard, F. C. et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J. Clin. Oncol. JCO2200338 (2022).https:\/\/doi.org\/10.1200\/JCO.22.00338","DOI":"10.1200\/JCO.22.00338"},{"key":"71233_CR12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","volume":"23","author":"M Will","year":"2023","unstructured":"Will, M., Liang, J., Metcalfe, C. & Chandarlapaty, S. Therapeutic resistance to anti-oestrogen therapy in breast cancer. Nat. Rev. Cancer 23, 673\u2013685 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"71233_CR13","doi-asserted-by":"publisher","first-page":"GS3-02","DOI":"10.1158\/1538-7445.SABCS22-GS3-02","volume":"83","author":"M Oliveira","year":"2023","unstructured":"Oliveira, M. et al. Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. Cancer Res. 83, GS3-02 (2023).","journal-title":"Cancer Res."},{"key":"71233_CR14","doi-asserted-by":"publisher","unstructured":"Jhaveri, K. L. et al. Phase Ia\/b study of giredestrant \u00b1palbociclib and \u00b1luteinizing hormone-releasing hormone agonists in estrogen receptor-positive, HER2-negative, locally advanced\/metastatic breast cancer. Clin. Cancer Res. (2023). https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1796","DOI":"10.1158\/1078-0432.CCR-23-1796"},{"key":"71233_CR15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1158\/1535-7163.MCT-20-0390","volume":"20","author":"M Shomali","year":"2021","unstructured":"Shomali, M. et al. SAR439859, a novel selective estrogen receptor degrader (SERD), demonstrates effective and broad antitumor activity in wild-type and mutant ER-positive breast cancer models. Mol. Cancer Ther. 20, 250\u2013262 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"71233_CR16","doi-asserted-by":"publisher","unstructured":"Bhagwat, S. V. et al. Imlunestrant is an oral, brain-penetrant selective estrogen receptor degrader with potent antitumor activity in ESR1 wildtype and mutant breast cancer. Cancer Res. (2024). https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-2608","DOI":"10.1158\/0008-5472.CAN-24-2608"},{"key":"71233_CR17","doi-asserted-by":"publisher","unstructured":"Mart\u00edn, M. et al. Giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer: results from the randomized, phase II acelERA breast cancer study. J. Clin. Oncol. JCO2301500 (2024). https:\/\/doi.org\/10.1200\/JCO.23.01500","DOI":"10.1200\/JCO.23.01500"},{"key":"71233_CR18","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1200\/JCO.22.02746","volume":"41","author":"SM Tolaney","year":"2023","unstructured":"Tolaney, S. M. et al. AMEERA-3: randomized phase II study of amcenestrant (oral selective estrogen receptor degrader) versus standard endocrine monotherapy in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. J. Clin. Oncol. 41, 4014\u20134024 (2023).","journal-title":"J. Clin. Oncol."},{"key":"71233_CR19","doi-asserted-by":"publisher","unstructured":"Jhaveri, K. L. et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N. Engl. J. Med. (2024). https:\/\/doi.org\/10.1056\/NEJMoa2410858","DOI":"10.1056\/NEJMoa2410858"},{"key":"71233_CR20","doi-asserted-by":"publisher","first-page":"e2351700","DOI":"10.1001\/jamanetworkopen.2023.51700","volume":"7","author":"WT Iams","year":"2024","unstructured":"Iams, W. T. et al. Concurrent tissue and circulating tumor DNA molecular profiling to detect guideline-based targeted mutations in a multicancer cohort. JAMA Netw. Open 7, e2351700 (2024).","journal-title":"JAMA Netw. Open"},{"key":"71233_CR21","doi-asserted-by":"publisher","unstructured":"Chen, J. W. et al. ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes. Mol. Oncol. (2023). https:\/\/doi.org\/10.1002\/1878-0261.13416","DOI":"10.1002\/1878-0261.13416"},{"key":"71233_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi, P. et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 34, 427\u2013438.e426 (2018).","journal-title":"Cancer Cell"},{"key":"71233_CR23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli, M. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 17, 425\u2013439 (2016).","journal-title":"Lancet Oncol."},{"key":"71233_CR24","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran, H. et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin. Cancer Res. 25, 6916\u20136924 (2019).","journal-title":"Clin. Cancer Res."},{"key":"71233_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41585-021-00490-0","volume":"18","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Ci, X., Choi, S. Y. C., Crea, F. & Lin, D. Molecular events in neuroendocrine prostate cancer development. Nat. Rev. Urol. 18, 581\u2013596 (2021).","journal-title":"Nat. Rev. Urol."},{"key":"71233_CR26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s43018-024-00898-8","volume":"6","author":"J Liang","year":"2025","unstructured":"Liang, J. et al. ER\u03b1 dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER+ breast cancer. Nat. Cancer 6, 357\u2013371 (2025).","journal-title":"Nat. Cancer"},{"key":"71233_CR27","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1126\/science.abn0478","volume":"377","author":"JM Chan","year":"2022","unstructured":"Chan, J. M. et al. Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling. Science 377, 1180\u20131191 (2022).","journal-title":"Science"},{"key":"71233_CR28","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s43018-021-00215-7","volume":"2","author":"JI Griffiths","year":"2021","unstructured":"Griffiths, J. I. et al. Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4\/6 therapy. Nat. Cancer 2, 658\u2013671 (2021).","journal-title":"Nat. Cancer"},{"key":"71233_CR29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker, A. B., Sudhan, D. R. & Arteaga, C. L. Overcoming endocrine resistance in breast cancer. Cancer Cell 37, 496\u2013513 (2020).","journal-title":"Cancer Cell"},{"key":"71233_CR30","doi-asserted-by":"publisher","first-page":"W212","DOI":"10.1093\/nar\/gkz446","volume":"47","author":"AB Keenan","year":"2019","unstructured":"Keenan, A. B. et al. ChEA3: transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res. 47, W212\u2013W224 (2019).","journal-title":"Nucleic Acids Res."},{"key":"71233_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2013-14-1-r6","volume":"14","author":"DA Sanders","year":"2013","unstructured":"Sanders, D. A., Ross-Innes, C. S., Beraldi, D., Carroll, J. S. & Balasubramanian, S. Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells. Genome Biol. 14, R6 (2013).","journal-title":"Genome Biol."},{"key":"71233_CR32","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1038\/onc.2010.47","volume":"29","author":"J Millour","year":"2010","unstructured":"Millour, J. et al. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene 29, 2983\u20132995 (2010).","journal-title":"Oncogene"},{"key":"71233_CR33","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1016\/j.celrep.2019.02.054","volume":"26","author":"A Arceci","year":"2019","unstructured":"Arceci, A. et al. FOXM1 deubiquitination by USP21 regulates cell cycle progression and paclitaxel sensitivity in basal-like breast cancer. Cell Rep. 26, 3076\u20133086.e3076 (2019).","journal-title":"Cell Rep."},{"key":"71233_CR34","doi-asserted-by":"publisher","first-page":"842","DOI":"10.18632\/oncotarget.23182","volume":"9","author":"XF Lu","year":"2018","unstructured":"Lu, X. F. et al. FoxM1 is a promising candidate target in the treatment of breast cancer. Oncotarget 9, 842\u2013852 (2018).","journal-title":"Oncotarget"},{"key":"71233_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01402-1","volume":"23","author":"K Kaminska","year":"2021","unstructured":"Kaminska, K. et al. Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. Breast Cancer Res. 23, 26 (2021).","journal-title":"Breast Cancer Res."},{"key":"71233_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07534-y","volume":"16","author":"Z Yan","year":"2025","unstructured":"Yan, Z. et al. ATP6AP1 promotes cell proliferation and tamoxifen resistance in luminal breast cancer by inducing autophagy. Cell Death Dis. 16, 201 (2025).","journal-title":"Cell Death Dis."},{"key":"71233_CR37","doi-asserted-by":"publisher","first-page":"e15828","DOI":"10.7554\/eLife.15828","volume":"5","author":"JD Joseph","year":"2016","unstructured":"Joseph, J. D. et al. The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. Elife 5, e15828 (2016).","journal-title":"Elife"},{"key":"71233_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ng.730","volume":"43","author":"A Hurtado","year":"2011","unstructured":"Hurtado, A., Holmes, K. A., Ross-Innes, C. S., Schmidt, D. & Carroll, J. S. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet 43, 27\u201333 (2011).","journal-title":"Nat. Genet"},{"key":"71233_CR39","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1016\/j.celrep.2019.02.036","volume":"26","author":"SE Glont","year":"2019","unstructured":"Glont, S. E., Chernukhin, I. & Carroll, J. S. Comprehensive Genomic Analysis Reveals that the Pioneering Function of FOXA1 Is Independent of Hormonal Signaling. Cell Rep. 26, 2558\u20132565.e2553 (2019).","journal-title":"Cell Rep."},{"key":"71233_CR40","doi-asserted-by":"publisher","first-page":"76498","DOI":"10.18632\/oncotarget.20405","volume":"8","author":"Y Wang","year":"2017","unstructured":"Wang, Y., Ung, M. H., Xia, T., Cheng, W. & Cheng, C. Cancer cell line specific co-factors modulate the FOXM1 cistrome. Oncotarget 8, 76498\u201376515 (2017).","journal-title":"Oncotarget"},{"key":"71233_CR41","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nmeth.3853","volume":"13","author":"M Hafner","year":"2016","unstructured":"Hafner, M., Niepel, M., Chung, M. & Sorger, P. K. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13, 521\u2013527 (2016).","journal-title":"Nat. Methods"},{"key":"71233_CR42","first-page":"1","volume":"11","author":"J Guan","year":"2025","unstructured":"Guan, J. et al. Giredestrant immobilizes the Estrogen Receptor to potently suppress ER-active breast cancers.  San. Antonio Breast Cancer Symp. PS 11, 1\u201312 (2025).","journal-title":"San. Antonio Breast Cancer Symp. PS"},{"key":"71233_CR43","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s43018-023-00577-0","volume":"4","author":"TJ Hagenbeek","year":"2023","unstructured":"Hagenbeek, T. J. et al. An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance. Nat. Cancer 4, 812\u2013828 (2023).","journal-title":"Nat. Cancer"},{"key":"71233_CR44","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","volume":"30","author":"E Dardenne","year":"2016","unstructured":"Dardenne, E. et al. N-Myc Induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell 30, 563\u2013577 (2016).","journal-title":"Cancer Cell"},{"key":"71233_CR45","doi-asserted-by":"publisher","unstructured":"Gianni, C. et al. Cell-Free DNA fragmentomics: a promising biomarker for diagnosis, prognosis and prediction of response in breast cancer. Int. J. Mol. Sci. 23 (2022). https:\/\/doi.org\/10.3390\/ijms232214197","DOI":"10.3390\/ijms232214197"},{"key":"71233_CR46","doi-asserted-by":"publisher","unstructured":"Qi, T. et al. Cell-free DNA fragmentomics: the novel promising biomarker. Int. J. Mol. Sci. 24 (2023). https:\/\/doi.org\/10.3390\/ijms24021503","DOI":"10.3390\/ijms24021503"},{"key":"71233_CR47","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jmoldx.2018.05.004","volume":"20","author":"TA Clark","year":"2018","unstructured":"Clark, T. A. et al. Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA. J. Mol. Diagn. 20, 686\u2013702 (2018).","journal-title":"J. Mol. Diagn."},{"key":"71233_CR48","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/bioinformatics\/btq057","volume":"26","author":"TD Wu","year":"2010","unstructured":"Wu, T. D. & Nacu, S. Fast and SNP-tolerant detection of complex variants and splicing in short reads. Bioinformatics 26, 873\u2013881 (2010).","journal-title":"Bioinformatics"},{"key":"71233_CR49","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/978-1-4939-3578-9_15","volume":"1418","author":"TD Wu","year":"2016","unstructured":"Wu, T. D., Reeder, J., Lawrence, M., Becker, G. & Brauer, M. J. GMAP and GSNAP for genomic sequence alignment: enhancements to speed, accuracy, and functionality. Methods Mol. Biol. 1418, 283\u2013334 (2016).","journal-title":"Methods Mol. Biol."},{"key":"71233_CR50","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71233_CR51","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"71233_CR52","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"71233_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0051-4","volume":"2","author":"MC Wagle","year":"2018","unstructured":"Wagle, M. C. et al. A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. NPJ Precis. Oncol. 2, 7 (2018).","journal-title":"NPJ Precis. Oncol."},{"key":"71233_CR54","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12, e1004873 (2016).","journal-title":"PLoS Comput. Biol."},{"key":"71233_CR55","doi-asserted-by":"publisher","unstructured":"Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 2017 (2017). https:\/\/doi.org\/10.1200\/PO.17.00011","DOI":"10.1200\/PO.17.00011"},{"key":"71233_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-9-r137","volume":"9","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).","journal-title":"Genome Biol."},{"key":"71233_CR57","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature11247","volume":"489","author":"EP Consortium","year":"2012","unstructured":"Consortium, E. P. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57\u201374 (2012).","journal-title":"Nature"},{"key":"71233_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-165","volume":"11","author":"RC McLeay","year":"2010","unstructured":"McLeay, R. C. & Bailey, T. L. Motif enrichment analysis: a unified framework and an evaluation on ChIP data. BMC Bioinforma. 11, 165 (2010).","journal-title":"BMC Bioinforma."},{"key":"71233_CR59","doi-asserted-by":"publisher","first-page":"D252","DOI":"10.1093\/nar\/gkx1106","volume":"46","author":"IV Kulakovskiy","year":"2018","unstructured":"Kulakovskiy, I. V. et al. HOCOMOCO: towards a complete collection of transcription factor binding models for human and mouse via large-scale ChIP-Seq analysis. Nucleic Acids Res. 46, D252\u2013D259 (2018).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71233-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71233-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71233-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:03:07Z","timestamp":1779753787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71233-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71233"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71233-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: excepting K.L. Jhaveri, N.C. Turner, and E. Lim, all authors are Genentech\/Roche employees and own shares of Roche. C.M. is a named co-inventor on patent 11081236 entitled \u201cDiagnostic and therapeutic methods for the treatment of breast cancer\u201d. K.L. Jhaveri has a consultant\/advisory board role in Novartis, Pfizer, BMS, Jounce Therapeutics, Taiho Oncology, Genentech, Inc., AbbVie, Eisai, AstraZeneca, Blueprint Medicine, Daiichi Sankyo, Sun Pharma Advanced Research Company Ltd, Gilead, Seattle Genetics, Olema Pharmaceuticals, Menarini\/Stemline, and Lilly\/Loxo Oncology; and has received research funding from Novartis, Clovis Oncology, Genentech, Inc., AstraZeneca, ADC Therapeutics, Novita Pharmaceuticals, Debio Pharmaceuticals, Pfizer, Lilly Pharmaceuticals\/Loxo Oncology, Zymeworks, Gilead, Puma Biotechnology, Context Therapeutics, and Merck Pharmaceuticals. N.C. Turner has received advisory board honoraria from AstraZeneca, Lilly, Pfizer, Roche\u2013Genentech, Novartis, GlaxoSmithKline, Repare Therapeutics, Relay Therapeutics, Zentalis, Gilead, Inivata, Guardant, and Exact Sciences; and research funding from AstraZeneca, Pfizer, Roche\u2013Genentech, Merck Sharpe & Dohme, Guardant Health, Invitae, Inivata, Personalis, and Natera. E. Lim reports research support from Ellipses, Novartis, and Pfizer; speaker compensation from AstraZeneca, Gilead, Novartis, Lilly, Pfizer and Roche; meeting and\/or travel support from AstraZeneca, Novartis, and Gilead; advisory board compensation from AstraZeneca, Gilead, Lilly, MSD, Novartis, Pfizer and Roche; and leadership or fiduciary roles in the Breast Cancer Trials and University of New South Wales.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4675"}}